BioSpace News Archive

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced the publication of the first cross-sectional, retrospective study to describe selective elevation of fast but not slow skeletal muscle fiber injury biomarkers in the blood of patients with Becker and Duchenne muscular dystrophy (BMD, DMD) in the journal, Muscle & Nerve

“All business areas achieved good performance in the first quarter, with very strong growth in Medical Solutions and Integrated Solutions,” said Nolato President and CEO Christer Wahlquist.

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has commenced clinical trial site recruitment for its upcoming Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (NSCLC).

Ocutrx Technologies, Inc. an augmented/extended reality and surgical device manufacturing company focused on transforming healthcare technology, announced today the issuance of its fifth patent by the U.S. Patent & Trademark Office. The fifth patent covers a Macular Visual Field (MVF) test administered while the user is wearing the Oculenz™ AMD AR/XR headset.

PENTAX Medical, a healthcare industry leader in diagnostic and therapeutic endoscopy, is pleased to announce the appointment of Ojas A. Buch as President of the Americas.

Strata to present data on comprehensive genomic and transcriptomic profiling in patients with advanced solid tumors

ivWatch’s Family of IV Site Monitoring Products Now Available to More Than 4,000 Premier Hospitals with New Three-Year Agreement

FEMSelect, the developer of EnPlace™, a minimally invasive, meshless approach to pelvic floor ligament fixation, and LiNA Medical USA today announced a strategic sales partnership to reach pelvic floor surgeons across the United States with the EnPlace™ system.

Life Spine Announces FDA 510(k) Clearance for the PROLIFT ® Lateral HELO Fixation System

Invectys, Inc., a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced the appointment of Praveen Tyle, PhD, as President & CEO and election to its Board of Directors.